Exelixis Inc Dossier
Qualitative Analysis
Business overview
Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company dedicated to the discovery, development, and commercialization of next-generation medicines for difficult-to-treat cancers. The company's primary commercial engine is its cabozantinib franchise, which includes CABOMETYX (approved for advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer) and COMETRIQ (approved for progressive, metastatic medullary thyroid cancer). Exelixis also markets COTELLIC in partnership with Genentech. The company is rapidly expanding its clinical pipeline, led by zanzalintinib, a novel oral kinase inhibitor currently in late-stage development for metastatic colorectal cancer and other solid tumors.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the clinical development of zanzalintinib, a next-generation oral tyrosine kinase inhibitor, across multiple solid tumor indications (including colorectal cancer, renal cell carcinoma, lung cancer, and prostate cancer) through several ongoing and planned Phase 3 pivotal trials.
Expected impact: Establishment of a multi-franchise solid tumor oncology business to drive long-term revenue growth beyond the flagship product CABOMETYX.
Returning capital to shareholders through aggressive stock buybacks. Following the completion of a $750 million program in May 2026, the Board authorized a new $750 million stock repurchase program.
Expected impact: Reduction in outstanding share count to enhance earnings per share and deliver capital return to shareholders.
Expanding the internal gastrointestinal (GI) sales team to accelerate CABOMETYX momentum in neuroendocrine tumors (NET) and prepare the commercial infrastructure for the potential launch of zanzalintinib in colorectal cancer.
Expected impact: Maximize market share for CABOMETYX in newly approved NET indications and ensure a rapid, successful commercial launch of zanzalintinib upon FDA approval.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High-value collaboration to evaluate zanzalintinib in combination with Merck's therapies. In May 2026, the partnership was expanded to supply Merck's subcutaneous anti-PD-1 therapy, KEYTRUDA QLEX, for the planned Phase 3 STELLAR-316 trial in resected stage II/III colorectal cancer.
Terms: Merck supplies KEYTRUDA QLEX for the trial; Exelixis sponsors the study. Specific financial terms were not disclosed.
High. Natera will provide its Signatera circulating tumor DNA (ctDNA) molecular residual disease (MRD) assay to identify MRD-positive patients for enrollment in the Phase 3 STELLAR-316 trial.
Terms: Specific financial terms were not disclosed.
High. Ipsen is Exelixis' global partner for cabozantinib outside the U.S. and Japan. In July 2025, Ipsen secured European Commission approval for CABOMETYX in advanced neuroendocrine tumors, expanding the global franchise footprint.
Terms: Exelixis receives royalties on net sales of cabozantinib in Ipsen's territories, as well as potential milestone payments.